FDA Grants IND Clearance for Silo Pharma's Noribogaine in Alcohol Use Disorder
SILO has more than doubled off its 52-week low of $0.221 on light trading volume (0.1× avg).
Summary
Silo Pharma has received Investigational New Drug (IND) clearance from the FDA for Demerx NB's Noribogaine, a candidate therapy for Alcohol Use Disorder. This significant regulatory milestone allows the company to proceed with human clinical trials for Noribogaine. While the original headline also notes the advancement of Silo Pharma's PTSD program in the context of FDA fast-tracking psychedelic therapies, the IND clearance for Noribogaine represents a concrete and material step forward in the company's pipeline. For a small-cap biotech, an IND clearance is a major de-risking event that can substantially impact future valuation and investor sentiment. Investors will now focus on the initiation and results of the upcoming clinical trials for Noribogaine.
At the time of this announcement, SILO was trading at $0.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2M. The 52-week trading range was $0.22 to $1.15. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.